Oral glutamine supplementation improves intestinal permeability dysfunction in a murine acute graft-vs.-host disease model

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 304, Issue 7, 2013, Pages

  Noth, Rainer ^a   Häsler, Robert ^a   Stüber, Eckhard ^a   Ellrichmann, Mark ^a   Schäfer, Heiner ^a   Geismann, Claudia ^a   Hampe, Jochen ^a   Bewig, Burkhard ^a   Wedel, Thilo ^b   Böttner, Martina ^b   Schreiber, Stefan ^a   Rosenstiel, Philip ^a   Arlt, Alexander ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Glutamine; Graft vs; Host; Permeability; TNF

Indexed keywords

GLUTAMINE; OCCLUDIN; TUMOR NECROSIS FACTOR ALPHA; OCLN PROTEIN, MOUSE;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; INTESTINE MUCOSA PERMEABILITY; IRRADIATION; JEJUNUM; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TIGHT JUNCTION; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; GASTROINTESTINAL TRACT; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; LYMPHOCYTE TRANSFUSION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PERMEABILITY;

ANIMALS; DISEASE MODELS, ANIMAL; GASTROINTESTINAL TRACT; GLUTAMINE; GRAFT VS HOST DISEASE; JEJUNUM; LYMPHOCYTE TRANSFUSION; MICE; OCCLUDIN; PERMEABILITY; TUMOR NECROSIS FACTOR-ALPHA;

MLCS; MLOWN;

EID: 84878128519     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00246.2012     Document Type: Article

References (54)

1. Akisu M, Baka M, Huseyinov A, Kultursay N. The role of dietary supplementation with L-glutamine in inflammatory mediator release and intestinal injury in hypoxia/reoxygenation-induced experimental necrotizing enterocolitis. Ann Nutr Metab 47: 262-266, 2003.
2. Amasheh M, Andres S, Amasheh S, Fromm M, Schulzke JD. Barrier effects of nutritional factors. Ann NY Acad Sci 1165: 267-273, 2009.
3. Ameho CK, Adjei AA, Harrison EK, Takeshita K, Morioka T, Arakaki Y, Ito E, Suzuki I, Kulkarni AD, Kawajiri A, Yamamoto S. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 41: 487-493, 1997.
4. Anderson PM, Ramsay NK, Shu XO, Rydholm N, Rogosheske J, Nicklow R, Weisdorf DJ, Skubitz KM. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant 22: 339-344, 1998.
5. Barreau F, Madre C, Meinzer U, Berrebi D, Dussaillant M, Merlin F, Eckmann L, Karin M, Sterkers G, Bonacorsi S, Lesuffleur T, Hugot JP. Nod2 regulates the host response towards microflora by modulating T cell function and epithelial permeability in mouse Peyer's patches. Gut 59: 207-217, 2010.
6. Basuroy S, Sheth P, Mansbach CM, Rao RK. Acetaldehyde disrupts tight junctions and adherens junctions in human colonic mucosa: protection by EGF and L-glutamine. Am J Physiol Gastrointest Liver Physiol 289: G367-G375, 2005.
7. Brown GR, Lee E, Thiele DL. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J¡C57BL/6J → bm12)F1 mice. J Immunol 168: 3065-3071, 2002.
8. Brown GR, Lindberg G, Meddings J, Silva M, Beutler B, Thiele D. Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versushost disease. Gastroenterology 116: 593-601, 1999.
9. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 82: 45-52, 2007.
10. Clark EC, Patel SD, Chadwick PR, Warhurst G, Curry A, Carlson GL. Glutamine deprivation facilitates tumour necrosis factor induced bacterial translocation in Caco-2 cells by depletion of enterocyte fuel substrate. Gut 52: 224-230, 2003.
11. Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, Rossignol DP, Ferrara JL. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 107: 1581-1589, 2001.
12. Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, Alousi A. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 15: 1555-1562, 2009.
13. Crowther M, Avenell A, Culligan DJ. Systematic review and metaanalyses of studies of glutamine supplementation in haematopoietic stem cell transplantation. Bone Marrow Transplant 44: 413-425, 2009.
14. da Silva Lima F, Rogero MM, Ramos MC, Borelli P, and Fock RA. Modulation of the nuclear factor-kappa B (NF-kappaB) signalling pathway by glutamine in peritoneal macrophages of a murine model of protein malnutrition. Eur J Nutr 2012 Aug 26. [Epub ahead of print].
15. Evans ME, Jones DP, Ziegler TR. Glutamine inhibits cytokine-induced apoptosis in human colonic epithelial cells via the pyrimidine pathway. Am J Physiol Gastrointest Liver Physiol 289: G388-G396, 2005.
16. Fan J, Meng Q, Guo G, Xie Y, Li X, Xiu Y, Li T, Feng W, Ma L. Effects of glutamine added to enteral nutrition on Peyer's patch apoptosis in severely burned mice. Burns 36: 409-417, 2010.
17. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 373: 1550-1561, 2009.
18. Gibson PR. Increased gut permeability in Crohn's disease: is TNF the link? Gut 53: 1724-1725, 2004.
19. Guy-Grand D, Vassalli P. Gut injury in mouse graft-versus-host reaction. Study of its occurrence and mechanisms. J Clin Invest 77: 1584-1595, 1986.
20. Herve P, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P, Plouvier E, Stephan JL, Bourdeau H, Holler E, Lioure B, Roche C, Vilmer E, Demeocq F, Kuentz M, Cahn JY. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 79: 3362-3368, 1992.
21. Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, Crawford JM, Ferrara JL. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 104: 459-467, 1999.
22. Horio Y, Osawa S, Takagaki K, Hishida A, Furuta T, Ikuma M. Glutamine supplementation increases Th1-cytokine responses in murine intestinal intraepithelial lymphocytes. Cytokine 44: 92-95, 2008.
23. Kretzmann NA, Fillmann H, Mauriz JL, Marroni CA, Marroni N, Gonzalez-Gallego J, Tunon MJ. Effects of glutamine on proinflammatory gene expression and activation of nuclear factor kappa B and signal transducers and activators of transcription in TNBS-induced colitis. Inflamm Bowel Dis 14: 1504-1513, 2008.
24. Li N, Gu L, Qu L, Gong J, Li Q, Zhu W, Li J. Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells. Eur J Pharm Sci 40: 1-8, 2010.
25. Li N, Lewis P, Samuelson D, Liboni K, Neu J. Glutamine regulates Caco-2 cell tight junction proteins. Am J Physiol Gastrointest Liver Physiol 287: G726-G733, 2004.
26. Li N, Neu J. Glutamine deprivation alters intestinal tight junctions via a PI3-K/Akt mediated pathway in Caco-2 cells. J Nutr 139: 710-714, 2009.
27. Li Y, Ping X, Yu B, Liu F, Ni X, Li J. Clinical trial: prophylactic intravenous alanyl-glutamine reduces the severity of gastrointestinal toxicity induced by chemotherapy-a randomized crossover study. Aliment Pharmacol Ther 30: 452-458, 2009.
28. Ma HH, Ziegler J, Li C, Sepulveda A, Bedeir A, Grandis J, Lentzsch S, Mapara MY. Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GvHD): early role for STAT1 and STAT3. Cell Immunol 268: 37-46, 2011.
29. Marchiando AM, Shen L, Graham WV, Edelblum KL, Duckworth CA, Guan Y, Montrose MH, Turner JR, Watson AJ. The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal epithelial shedding. Gastroenterology 140: 1208-1218. e1-2, 2011.
30. Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med 34: 1980-1990, 2008.
31. Merger M, Viney JL, Borojevic R, Steele-Norwood D, Zhou P, Clark DA, Riddell R, Maric R, Podack ER, Croitoru K. Defining the roles of perforin, Fas/FasL, and tumour necrosis factor alpha in T cell induced mucosal damage in the mouse intestine. Gut 51: 155-163, 2002.
32. Murray SM, Pindoria S. Nutrition support for bone marrow transplant patients. Cochrane Database Syst Rev 1: CD002920, 2009.
33. Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C, Appelbaum FR, Doney K, Martin P, Slattery J, Sullivan K, van der Jagt R, Witherspoon R, Jusko WJ, Zager RA, Deeg HJ. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 85: 3746-3753, 1995.
34. Nishi T, Okazaki K, Fujii S, Uchida K, Uose S, Nakase H, Ohana M, Nishihara T, Chiba T. Successful treatment with steroids of upper gastrointestinal acute graft vs. host disease after hematopoietic stem cell transplantation. Endoscopy 33: 985-987, 2001.
35. Noth R, Lange-Grumfeld J, Stuber E, Kruse ML, Ellrichmann M, Hasler R, Hampe J, Bewig B, Rosenstiel P, Schreiber S, Arlt A. Increased intestinal permeability and tight junction disruption by altered expression and localization of occludin in a murine graft versus host disease model. BMC Gastroenterol 11: 109, 2011.
36. Pahl R, Brunke G, Steubesand N, Schubert S, Bottner M, Wedel T, Jurgensen C, Hampe J, Schafer H, Zeissig S, Schreiber S, Rosenstiel P, Reiss K, Arlt A. IL-1β and ADAM17 are central regulators of β-defensin expression in Candida esophagitis. Am J Physiol Gastrointest Liver Physiol 300: G547-G553, 2011.
37. Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol 21: 149-161, 2003.
38. Seth A, Basuroy S, Sheth P, Rao RK. L-Glutamine ameliorates acetaldehyde-induced increase in paracellular permeability in Caco-2 cell monolayer. Am J Physiol Gastrointest Liver Physiol 287: G510-G517, 2004.
39. Sina C, Arlt A, Gavrilova O, Midtling E, Kruse ML, Muerkoster SS, Kumar R, Folsch UR, Schreiber S, Rosenstiel P, Schafer H. Ablation of gly96/immediate early gene-X1 (gly96/iex-1) aggravates DSS-induced colitis in mice: role for gly96/iex-1 in the regulation of NF-kappaB. Inflamm Bowel Dis 16: 320-331, 2010.
40. Singleton KD, Wischmeyer PE. Glutamine attenuates inflammation and NF-kappaB activation via Cullin-1 deneddylation. Biochem Biophys Res Commun 373: 445-449, 2008.
41. Snider D, Liang H. Early intestinal Th1 inflammation and mucosal T cell recruitment during acute graft-versus-host reaction. J Immunol 166: 5991-5999, 2001.
42. Soderholm JD, Streutker C, Yang PC, Paterson C, Singh PK, McKay DM, Sherman PM, Croitoru K, Perdue MH. Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha. Gut 53: 1817-1824, 2004.
43. Steubesand N, Kiehne K, Brunke G, Pahl R, Reiss K, Herzig KH, Schubert S, Schreiber S, Folsch UR, Rosenstiel P, Arlt A. The expression of the beta-defensins hBD-2 and hBD-3 is differentially regulated by NF-kappaB and MAPK/AP-1 pathways in an in vitro model of Candida esophagitis. BMC Immunol 10: 36, 2009.
44. Stuber E, Buschenfeld A, von Freier A, Arendt T, Folsch UR. Intestinal crypt cell apoptosis in murine acute graft versus host disease is mediated by tumour necrosis factor alpha and not by the FasL-Fas interaction: effect of pentoxifylline on the development of mucosal atrophy. Gut 45: 229-235, 1999.
45. Stuber E, Schlenger P, Von Freier A, Arendt T, Folsch UR. Interferongamma is not involved in the intestinal manifestations of the acute murine semiallogenic graft-versus-host disease. In J Colorectal Dis 16: 346-351, 2001.
46. Stuber E, Von Freier A, Marinescu D, Folsch UR. Involvement of OX40-OX40L interactions in the intestinal manifestations of the murine acute graft-versus-host disease. Gastroenterology 115: 1205-1215, 1998.
47. Tang Y, Clayburgh DR, Mittal N, Goretsky T, Dirisina R, Zhang Z, Kron M, Ivancic D, Katzman RB, Grimm G, Lee G, Fryer J, Nusrat A, Turner JR, Barrett TA. Epithelial NF-kappaB enhances transmucosal fluid movement by altering tight junction protein composition after T cell activation. Am J Pathol 176: 158-167, 2010.
48. Ueno PM, Oria RB, Maier EA, Guedes M, de Azevedo OG, Wu D, Willson T, Hogan SP, Lima AA, Guerrant RL, Polk DB, Denson LA, Moore SR. Alanyl-glutamine promotes intestinal epithelial cell homeostasis in vitro and in a murine model of weanling undernutrition. Am J Physiol Gastrointest Liver Physiol 301: G612-G622, 2011.
49. Vicario M, Amat C, Rivero M, Moreto M, Pelegri C. Dietary glutamine affects mucosal functions in rats with mild DSS-induced colitis. J Nutr 137: 1931-1937, 2007.
50. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 107: 827-834, 2006.
51. Wachtel M, Bolliger MF, Ishihara H, Frei K, Bluethmann H, Gloor SM. Down-regulation of occludin expression in astrocytes by tumour necrosis factor (TNF) is mediated via TNF type-1 receptor and nuclear factor-kappaB activation. J Neurochem 78: 155-162, 2001.
52. Washington K, Jagasia M. Pathology of graft-versus-host disease in the gastrointestinal tract. Hum Pathol 40: 909-917, 2009.
53. Yang YG, Wang H, Asavaroengchai W, Dey BR. Role of interferongamma in GvHD and GVL. Cell Mol Immunol 2: 323-329, 2005.
54. Zhang F, Wang X, Wang W, Li N, Li J. Glutamine reduces TNF-alpha by enhancing glutathione synthesis in lipopolysaccharide-stimulated alveolar epithelial cells of rats. Inflammation 31: 344-350, 2008.